A nitrous acid generator includes a treatment vessel having an inner space being capable of holding a liquid; a gas supplier supplying a gas to the inner space such that the gas forms a bubble in the liquid, the gas containing oxygen and nitrogen; a plasma generator including a first electrode, a second electrode, and a power supply for applying a voltage therebetween, the plasma generator generating plasma in the bubble, the plasma producing nitrogen oxide including nitrogen monoxide and nitrogen dioxide; a gas-liquid contact member to which the nitrogen oxide and the liquid are introduced from the treatment vessel, the gas-liquid contact member causing the nitrogen oxide to be dissolved in the liquid while the nitrogen oxide and the liquid pass through the gas-liquid contact member; and a cooler cooling the nitrogen oxide and the liquid while the nitrogen oxide and the liquid pass through the gas-liquid contact member.

A nitrous acid generator includes a treatment vessel having an inner space being capable of holding a liquid; a gas supplier supplying a gas to the inner space such that the gas forms a bubble in the liquid, the gas containing oxygen and nitrogen; a plasma generator including a first electrode, a second electrode, and a power supply for applying a voltage therebetween, the plasma generator generating plasma in the bubble, the plasma producing nitrogen oxide including nitrogen monoxide and nitrogen dioxide; a gas-liquid contact member to which the nitrogen oxide and the liquid are introduced from the treatment vessel, the gas-liquid contact member causing the nitrogen oxide to be dissolved in the liquid while the nitrogen oxide and the liquid pass through the gas-liquid contact member; and a cooler cooling the nitrogen oxide and the liquid while the nitrogen oxide and the liquid pass through the gas-liquid contact member.

Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.

Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.

Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.

Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.

Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.

Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.

A two-part aqueous composition for treating skin ailments, such as acne vulgaris, includes an acidic part having salicylic acid and an -hydroxy acid, and an alkaline part having an alkaline nitrite salt. The -hydroxy acid is preferably glycolic acid, lactic acid, malic acid, mandelic acid or a combination thereof. The alkaline nitrite salt is preferably sodium nitrite. The acidic part and the alkaline part are an acidic aqueous solution and an alkaline aqueous solution, respectively, which may either be mixed with one another then applied to an affected portion of a patient's skin or, alternatively, may be sequentially applied to the affected portion of the patient's skin, preferably within 15 minutes of one another.

Pyrophoric material such as iron sulfide is frequently found in refinery equipment. When the equipment is opened to the atmosphere for maintenance, an exothermic reaction can take place that may cause injury to personnel and catastrophic damage to equipment. A process used to treat pyrophoric material uses sodium nitrite injected into a gaseous carrier stream to oxidize iron sulfides to elemental sulfur and iron oxides. The sodium nitrite solution may be buffered to a pH of about 9 with disodium phosphate or monosodium phosphate. A chemical additive that provides a quantitative measure of reaction completion may be added to the treatment solution.